Sage Rhino Capital LLC Acquires 5,041 Shares of Gilead Sciences, Inc. $GILD

Sage Rhino Capital LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 213.7% in the third quarter, HoldingsChannel.com reports. The firm owned 7,400 shares of the biopharmaceutical company’s stock after purchasing an additional 5,041 shares during the period. Sage Rhino Capital LLC’s holdings in Gilead Sciences were worth $821,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Csenge Advisory Group grew its stake in shares of Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after acquiring an additional 16,288 shares during the period. Railway Pension Investments Ltd boosted its position in Gilead Sciences by 3.1% during the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after purchasing an additional 42,200 shares during the period. TriaGen Wealth Management LLC purchased a new position in shares of Gilead Sciences in the third quarter worth about $1,274,000. Invesco Ltd. raised its position in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the period. Finally, Sivik Global Healthcare LLC grew its stake in Gilead Sciences by 25.0% in the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $5,544,000 after buying an additional 10,000 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GILD. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday. UBS Group restated a “buy” rating on shares of Gilead Sciences in a research report on Thursday, January 15th. Scotiabank assumed coverage on shares of Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective for the company. Morgan Stanley cut their price target on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. Finally, The Goldman Sachs Group increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.52.

Insider Activity

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the transaction, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 141,757 shares of company stock valued at $17,569,112. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 3.7%

Shares of GILD stock opened at $135.93 on Monday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm has a market cap of $168.65 billion, a P/E ratio of 21.07, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33. The business has a 50-day moving average price of $123.98 and a two-hundred day moving average price of $118.71. Gilead Sciences, Inc. has a 12-month low of $92.26 and a 12-month high of $136.30.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.3%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.